
Quantitative Benefit-Risk

Jim Felli
Eli Lilly & Company

Quantitative BR

Lilly's quantitative benefit-risk model is:


- ❑ based on **multi-criteria decision analytic methods** (MCDA),
 - ❑ a **compensatory** model (surpluses offset deficits),
 - ❑ a **snapshot** in time and information state (readily updatable),
 - ❑ a **transparent** representation of beliefs informed by **data** and **expertise**, not a reformulation, replacement or optimization of an existing health outcome metric,
 - ❑ a **discussion generation tool**, not a decision making tool.
-

Quantitative BR

Frame

- Disease State
- Target Population
- Value Reference


BRAM




$$B_a = \sum_{m \in M} \alpha_m v_m \left\langle k_m^a \right\rangle$$

$$R_a = \sum_{n \in N} \beta_n \left[-v_n \left\langle k_n^a \right\rangle \right]$$



CUI




$$V_a = \sum_{k \in K} w_k v_k \left\langle k^a \right\rangle$$




Quantitative BR




Quantitative BR



Quantitative BR



Quantitative BR



Quantitative BR

Perspective	W
Patient	1
Prescriber	0
Developer	0
Regulator	0
Payer	0


Analytic Focus	Alternatives
Benefit:Risk	Alt 1
	Alt 2
	Alt 3

Data Set
(x,y) points

Graph Type
Profiles

Alternatives
Generic Names

No. of Profiles
1000



Alternatives	P[B+]	P[R-]	P[Opt]
Alt 1	0.027	0	0
Alt 2	0.011	0.622	0.0068
Alt 3	0.962	0.42	0.404

Quantitative BR

Perspective	W
Patient	1
Prescriber	5
Developer	1
Regulator	6
Payer	1


Analytic Focus	Alternatives
Benefit:Risk	Alt 1
	Alt 2
	Alt 3

Data Set
(x,y) points

Graph Type
Profiles

Alternatives
Generic Names

No. of Profiles
1000



Alternatives	P[B+]	P[R-]	P[Opt]
Alt 1	0	0	0
Alt 2	0	0.132	0
Alt 3	1	0.868	0.868

Quantitative BR


Perspective	W
Patient	1
Prescriber	0
Developer	0
Regulator	0
Payer	0

Analytic Focus	Alternatives
Benefit:Risk	Alt 1
	Alt 2
	Alt 3

Data Set
Positives

Graph Type
Inv. Cum. Distr.

Alternatives
Generic Names



Critical Score	0.56
Alternatives	P[>Crit]
Alt 1	0.995
Alt 2	0.942
Alt 3	0.999

Quantitative BR


Perspective	W
Patient	1
Prescriber	5
Developer	1
Regulator	6
Payer	1

Analytic Focus	Alternatives
Benefit:Risk	Alt 1
	Alt 2
	Alt 3

Data Set
Positives


Graph Type
Inv. Cum. Distr.

Alternatives
Generic Names



Critical Score	0.56
Alternatives	P[>Crit]
Alt 1	0.358
Alt 2	0.131
Alt 3	1

Quantitative BR



“Higher level” questions (e.g., governance)

On what attribute does my question focus? What lower level evidence would make me change my beliefs about this attribute?

“Lower level” questions (e.g., scientists)

Why do I care about this question? What beliefs about higher level attributes will the answer inform?

Quantitative BR

Lilly's quantitative benefit-risk model has been:

- ❑ designed to provide a common, organization-spanning **framework** for drug development,
 - ❑ designed to drive informed **discussion**,
 - ❑ extended to the **data** definition and collection level.
-

Quantitative BR

End
